- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Patt on the Role of Sacituzumab Govitecan in TNBC
Debra Patt, MD, PhD, MBA, breast medical oncologist, vice president of Texas Oncology, highlights the role of sacituzumab govitecan-hziy in triple-negative breast cancer.
- 2x
- 1.75x
- 1.5x
- 1.25x
- 1x, selected
- 0.75x
- 0.5x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Debra Patt, MD, PhD, MBA, breast medical oncologist, vice president of Texas Oncology, highlights the role of sacituzumab govitecan-hziy (Trodelvy) in triple-negative breast cancer (TNBC).
Sacituzumab govitecan, an antibody-drug conjugate, is a standard treatment option for patients with metastatic TNBC. Other breast cancer therapies, such as immunotherapy, can only be administered to a select group of patients with TNBC, Patt says.
As more targeted therapies enter the TNBC paradigm, it will be important to glean a better understanding of which patients will derive the most benefit from sacituzumab govitecan. However, as it stands, sacituzumab govitecan can be used more broadly for patients with TNBC compared with other therapies, Patt concludes.
Related Content:
